Published in Cancer Weekly, June 15th, 2004
A separate study by M. Hussein, MD, of the Cleveland Clinic Foundation, published in the British Journal of Haematology, showed that Trisenox as a monotherapy resulted in a clinical benefit to patients with relapsed or refractory multiple myeloma with objective responses in 33% of patients studied.
Cell Therapeutics, Inc., markets Trisenox in the U.S....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.